

PRIOR AUTHORIZATION REQUEST FORM EOC ID:

Benlysta

Phone: 800-728-7947 Fax back to: 866-880-4532

The Scott & White Health Plan Pharmacy Department manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above. Please note any information left blank or illegible may delay the review process.

	Prescriber Name:	
Patient Name:	Supervising Physician:	
Member/Subscriber Number:	Fax: Phone:	
Date of Birth:	Office Contact:	
Group Number:	NPI: State Lic ID:	
Address:	Address:	
City, State ZIP:	City, State ZIP:	
Primary Phone:	Specialty/facility name (if applicable):	
Drug Name and Strength:		
Directions / SIG:		
Please attach any pertinent medical history or information following qu	n for this patient that may support approval. Please ar uestions and sign.	nswer the
Q1. What diagnosis is this drug being prescribed for (pick of	one)?	
\pounds Active systemic lupus erythematosus (SLE)		
£ Other		
Q2. Please provide ICD code(s) for diagnosis:		
Q3. Is Benlysta being used in combination with at least one hydroxychloroquine, NSAIDs, azathioprine, methotrexate, r		
£ Yes £ No	,,	
Q4. Does the patient have documented intolerance, FDA-la care drugs listed above?	abeled contraindication, or hypersensitivity to the sta	andard of
£ Yes £ No		
Q5. Is the prescribing physician a rheumatologist?		
£ Yes £ No		
Q6. Does the patient have severe active lupus nephritis?		
£ Yes £ No		
Q7. Does the patient have severe active central nervous sy	ystem lupus?	



PRIOR AUTHORIZATION REQUEST FORM EOC ID:

Benlysta

Phone: 800-728-7947 Fax back to: 866-880-4532

The Scott & White Health Plan Pharmacy Department manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above. Please note any information left blank or illegible may delay the review process.

	Prescriber Name:
	Supervising Physician:
£ No	
peing used in combination with oran, Simponi, Stelara)?	other biologic therapies (e.g., Actemra, Cimzia, Enbrel, Orencia,
£ No	
peing used in combination with in	ntravenous cyclophosphamide?
£ No	
comments:	
	peing used in combination with can, Simponi, Stelara)? £ No peing used in combination with in

This telecopy transmission contains confidential information belonging to the sender that is legally privileged. This information is intended only for the use of the individual or entity named above. The authorized recipient of this information is prohibited from disclosing this information to any other party. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution or action taken in reference to the contents of this document is strictly prohibited. If you have received this telecopy in error, please notify the sender immediately to arrange for the return of this document

Lack of the necessary documentation may result in a medical necessity denial. Requesting providers may speak to the SWHP medical director at 1-888-316-7947 regarding the case to have an opportunity to help impact the decision on a request before coverage has been

decided.